This article is a correction to:
A Golden Tail of Immunotherapy: Significant Tail Effect in a Chemotherapy-Resistant Advanced Pulmonary Sarcomatoid Carcinoma Patient Treated by Sintilimab Combined with Anlotinib
Chenghao Fu
Haonan Du1†
Weiyou Zhu
Lei Cao- 1Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
- 2Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
- 3Department of Thoracic Surgery, Taizhou Fourth People’s Hospital, Taizhou, Jiangsu, China
- 4Department of Radiology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, Jiangsu, China
- 5Department of Pathology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, Jiangsu, China
- 6Department of Oncology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, Jiangsu, China
By Fu C, Du H, Wang Q, Zhu W, Bian G, Zhong Z, Wang Y and Cao L (2024). Front. Immunol. 15:1452195. doi: 10.3389/fimmu.2024.1452195
In the published article, there was an error in affiliations 4, 5, 6. Instead of “The First People’s Hospital of Suqian”, it should be “The Affiliated Suqian First People’s Hospital of Nanjing Medical University”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: tail effect, immunotherapy, cancer therapy, PSC, ICI, Sintilimab
Citation: Fu C, Du H, Wang Q, Zhu W, Bian G, Zhong Z, Wang Y and Cao L (2024) Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib. Front. Immunol. 15:1527232. doi: 10.3389/fimmu.2024.1527232
Received: 13 November 2024; Accepted: 14 November 2024;
Published: 26 November 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Fu, Du, Wang, Zhu, Bian, Zhong, Wang and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lei Cao, QnJhd255TTgwQDE2My5jb20=
†These authors have contributed equally to this work